GZTC Message Board - Msg: 6130726

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZTC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (576)	10/23/1998 12:10:00 AM
From: HIA	Read Replies (1) of 752

The 3.48 million shares is the maximum number of common shares that the preferred will convert into...the remaining preferred shares could be redeemed with cash... A shareholder vote could raise the maximum number of conversion shares...but that proposal would never be raised...only a proposal to approve the issue as written would be raised...(This is based on standard practice of other convertible issues...)... The "short provision" that is mentioned...simply refers to the common shares that the preferred holders receive...if and when they convert...and it just says that they may transact their common shares in any way that they choose... This issue is okay...it will increase the common shares by about 18%...in exchange for $20 million...and I expect that in a year or two Genezyme General will increase its holding...So I am planning on about 25 million shares total for a time frame of 3 to 5 years from now... Earnings per share? If rh ATIII becomes a commonly used product in by-pass surgery...say $400 million in annual sales...25% after-tax profit margin...half to genz and half to gztc...that's $50 million in annual income...divided by 25 million shares...for EPS of $2 a share!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next